Promethera

MGI has been a cornerstone investor since our Series B round and provided beyond the financial backing the strategic and business development support, through its teams and in particular with Fuchikami-san, to effectively help us expand our business in Japan. Being visible in Japan today, a country leading the next generation stem cell revolution, is rewarding and a must for Promethera. John Tchelingerian, CEO

WEB SITE

Global innovator of liver-cell based therapy bringing therapeutic solutions to patients with acute and chronic liver disease.

MGI helps Promethera find collaboration opportunities to scale-up production, navigate regulatory pathways in Japan, find business development opportunities with enterprise, and find introductions to key opinion leaders in the industry.

Kinji Fuchikami, Venture Partner Supported with: Network in the Biotech Industry
Biotech expertise
Autotalks

MGI has been a value-add investor since the early days of the company. Their supporting approach and in-depth insights about the Japanese market have helped tremendously throughout our penetration efforts in that market. They have proven to be a true partner in our long journey in the automotive market, always helping and providing valuable insight and advice. Hagai Zyss, CEO

WEB SITE

Vehicle-to-vehicle communications for autonomous driving to let you know ahead of time.

MGI helps AutoTalks develop and win business with Japanese automotive related companies and helps bring in strategic investors in Japan through its vast networks in the industry.

Atsushi Mizuno, Investment Director Supported with: Business expertise
Network in the industry
goBalto

MGI has gone far and beyond the normal investor relationship - within the first quarter post investment they had set up 5 prospect meetings - they know what’s important to take businesses to the next level. Sujay Jadhav, CEO

WEB SITE

Clinical study startup made easy.

MGI helps goBalto by opening doors to Japanese pharmaceutical companies and CROs.

Masashi Kiyomine, Investment Director Supported with: Healthcare SaaS investment experience
Kinji Fuchikami, Venture Partner Supported with: Relationship with pharma execs
SYMIC

MGI has been value-added investor by bringing a diverse life science sector perspective, and has been strategically helpful and hands-on regarding business development in Japan. Ken Horne, co-founder & CEO

WEB SITE

Symic Biomedical is developing a novel therapeutic platform focused on promoting and accelerating healing.

MGI is helping Symic Biomedical access global and Japanese pharmaceutical and medical device companies for potential co-development of their molecules.

Kinji Fuchikami, Venture Partner Supported with: Relationship with pharma execs
Scientific expertise
Mutsuki Takano, Senior Associate Supported with: Business creation
Negotiation experience
© 2018 Mitsui & Co. Global Investment, Inc.